+

US20100190757A1 - Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same - Google Patents

Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same Download PDF

Info

Publication number
US20100190757A1
US20100190757A1 US12/726,804 US72680410A US2010190757A1 US 20100190757 A1 US20100190757 A1 US 20100190757A1 US 72680410 A US72680410 A US 72680410A US 2010190757 A1 US2010190757 A1 US 2010190757A1
Authority
US
United States
Prior art keywords
estradiol
daily dosage
dosage units
phase
estradiol valerate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/726,804
Inventor
Susan Zeun
Pol Boudes
Angelo Secci
Jan Nedrikat
Holger Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/377,693 external-priority patent/US20070088011A1/en
Application filed by Individual filed Critical Individual
Priority to US12/726,804 priority Critical patent/US20100190757A1/en
Publication of US20100190757A1 publication Critical patent/US20100190757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Definitions

  • the subject matter of the present invention comprises the use of estradiol valerate or estradiol in combination with 17 ⁇ -cyanomethyl-17 ⁇ -hydroxyestra-4, 9-dien-3-one (dienogest) to make a multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception.
  • This multiphase combination preparation contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate or less than 3 mg of estradiol; a second phase of two groups of daily dosage units, a first group of which consists of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol, and a second group of which consists of 17 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol; a third phase of 2 daily dosage units, each consisting of 1 mg of estradiol valerate or of less than 1 mg estradiol; and another phase of 2 daily dosage units of pharmaceutically harmless placebo, which contains a total number of 28 daily dosage units.
  • the total number of daily dosage units of the multiphase combination preparation is sufficient for 28 days.
  • Dysfunctional uterine bleeding is a frequent clinical problem in gynecology and affects up to 33% of women presenting themselves for gynecological medical examinations on an outpatient basis (Awward J. T., Toth T. L., Schiff I., Abnormal Uterine Bleeding in the Perimenopause, Int. J. Fertil. 1993; 38, pp. 261-9).
  • the symptoms of DUB are:
  • DUB requires a diagnosis by exclusion, namely organic causes such as myoma, polyps or cancer must be excluded before a DUB diagnosis can be made.
  • DUB is associated with anovulation as well as ovulation.
  • Such bleeding disturbances are due to an imbalance between the estrogen-stimulating build-up phase (proliferation) of the endometrium and the gestagenic transformation of the endometrium. If the DUB symptoms are a result of chronic anovulation, the endometrium is often exposed to increased gestagenic proliferation. Such proliferation can lead to hyperplasia of the endometrium besides the bleeding disturbances (Speroff, et al., Clinical Gynecologic Endocrinology and Infertility, sixth edition, Lippincott, Williams and Wilkins, 1999).
  • Hyperplasia of the endometrium is a risk factor for the onset of endometrial cancer.
  • Steiner sees a treatment regimen in the oral administration of 0.01 mg of ethinyl estradiol with 2 mg of norethisterone acetate for 8 days in decreasing dosages, namely 6, 5, 4, 3, 3, 3, 3, 3/day. Besides the hormonal approach, Steiner postulates the possibility of treating an acute bleeding situation with tranexaminic acid, up to 4 ⁇ 2 tablets per day.
  • EE dosage remains constant over 21 days (0.035 mg of EE)
  • NGM dose increases over 21 days (7 daily dosage units of 0.180 mg of NMG and 7 daily dosage units of 0.215 mg of NMG and 7 daily dosage units of 0.250 mg of NMG), followed by a 7-day hormone-free placebo administration.
  • U.S. Pat. No. 6,782,282 discloses that generally extended use (3 months) of oral contraceptives can be used for the treatment of menorrhagia—a form of dysfunctional uterine bleeding.
  • the object of the present invention is to provide a multiphase combination preparation and a method for using it to treat dysfunctional uterine bleeding so that the extent of the bleeding is generally reduced and the recurrence of dysfunctional bleeding is generally prevented, while at the same time ensuring reliable, safe and well-tolerated oral contraception.
  • disfunctional uterine bleeding here means extended menstrual bleeding lasting more than 7 days with an interval between bleeding episodes of less than or equal to 21 days, or increased bleeding of more than or equal to 80 ml without an organic cause.
  • this objective is attained by a multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception, which is based on a combination of either estradiol valerate or estradiol with 17 ⁇ -cyano-methyl-17 ⁇ -hydroxyestra-4, 9-dien-3-one (dienogest).
  • the multiphase combination preparation contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate or of less than 3 mg estradiol; a second phase of 2 groups of daily dosage units, including a first group consisting of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol; a third phase consisting of 2 daily dosage units, each consisting of 1 mg of estradiol valerate or less than 1 mg of estradiol and another phase of 2 daily dosage units of a pharmaceutically harmless placebo.
  • the total number of daily dosage units of the multiphase combination preparation and the pharmaceutically harmless placebo should be sufficient for 28 days.
  • the duration of use comprises at least one treatment cycle and depends on the individual desires of the woman regarding contraception.
  • each daily dosage unit of the first phase consists of 2.25 mg of estradiol; each daily dosage unit of the second phase contains only 1.5 mg of estradiol; and each daily dosage units of the third phase consists of 0.75 mg of estradiol.
  • each daily dosage unit of the first phase consists of 3 mg of estradiol valerate; each daily dosage unit of the second phase contains 2 mg of estradiol valerate; and each daily dosage unit of the third phase consists of 1 mg of estradiol valerate.
  • the study comprised a run-in phase of 90 days during which the severity of the bleeding disturbances was recorded, 6 treatment cycles and one post-treatment cycle (follow-up phase).
  • the extent of bleeding was determined quantitatively by the alkaline hematin method. To this end, the women collected the monthly discharges during the entire study period and gave them to the testing center. The duration of the bleeding and the duration of the bleeding-free intervals were recorded by daily documentation in an electronic journal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase consisting of 2 daily dosage units, each containing 3 mg of estradiol valerate or <3 mg of estradiol; a second phase consisting of a first group of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or <2 mg of estradiol; a third phase consisting of 2 daily dosage units, each containing 1 mg of estradiol valerate or <1 mg of estradiol; and another phase consisting of 2 daily dosage units of a pharmaceutically harmless placebos.

Description

    CROSS-REFERENCE
  • This is a continuation-in-part of U.S. patent application Ser. No. 11/377,693, filed Mar. 16, 2006, which, in turn, claims the benefit of priority of invention under 35 U.S.C. 119 (e) based on U.S. Provisional Application, Ser. No. 60/727,592, filed Oct. 17, 2004.
    • BACKGROUND OF THE INVENTION
  • 1. The Field of the Invention
  • The subject matter of the present invention comprises the use of estradiol valerate or estradiol in combination with 17α-cyanomethyl-17β-hydroxyestra-4, 9-dien-3-one (dienogest) to make a multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception. This multiphase combination preparation contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate or less than 3 mg of estradiol; a second phase of two groups of daily dosage units, a first group of which consists of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol, and a second group of which consists of 17 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol; a third phase of 2 daily dosage units, each consisting of 1 mg of estradiol valerate or of less than 1 mg estradiol; and another phase of 2 daily dosage units of pharmaceutically harmless placebo, which contains a total number of 28 daily dosage units. The total number of daily dosage units of the multiphase combination preparation is sufficient for 28 days.
  • 2. Description of the Related Art
  • Dysfunctional uterine bleeding (DUB) is a frequent clinical problem in gynecology and affects up to 33% of women presenting themselves for gynecological medical examinations on an outpatient basis (Awward J. T., Toth T. L., Schiff I., Abnormal Uterine Bleeding in the Perimenopause, Int. J. Fertil. 1993; 38, pp. 261-9). The symptoms of DUB are:
      • extended menstrual bleeding (>7 days)
      • frequent bleeding (interval between bleeding episodes of less than or equal to 21 days)
      • increased bleeding (more than or equal to 80 ml).
  • DUB requires a diagnosis by exclusion, namely organic causes such as myoma, polyps or cancer must be excluded before a DUB diagnosis can be made.
  • DUB is associated with anovulation as well as ovulation. Such bleeding disturbances are due to an imbalance between the estrogen-stimulating build-up phase (proliferation) of the endometrium and the gestagenic transformation of the endometrium. If the DUB symptoms are a result of chronic anovulation, the endometrium is often exposed to increased gestagenic proliferation. Such proliferation can lead to hyperplasia of the endometrium besides the bleeding disturbances (Speroff, et al., Clinical Gynecologic Endocrinology and Infertility, sixth edition, Lippincott, Williams and Wilkins, 1999).
  • Hyperplasia of the endometrium is a risk factor for the onset of endometrial cancer.
  • Fraser, I. S., Aust. NZ J. Obstet. Gynaecol. (1990) 30 (4), pp. 353-356, reported the treatment of dysfunctional uterine bleeding by administration of 5 mg of norethisterone, three times daily, or 10 mg of medroxyprogesterone acetate, three times daily, as the only high-dosage gestagen, in each case for 14 days from the 12th to the 25th day of the cycle in 6 anovulatory women and for 20 days from the 5″1 to the 25th day of the cycle in ten ovulatory women. In both groups, the duration of the bleeding period was reduced. Reliable contraception was not attained.
  • Hickey M., Higham J. and Fraser I S, The Chochrane Library, Issue 3 2004 (Mickey M, Higham J, Fraser I S, Progestogens Versus Estrogens and Progestogens for Irregular Uterine Bleeding Associated with Anovulation (Cochrane Review). In The Cochrane Library, Issue 3 2004, Chichester, UK: John Wiley & Sons, Ltd) describe in a review article the low tolerance of women for irregular and extensive bleeding. They describe the rationale behind the use of gestagens to achieve a transformation of the endometrium and thus to create more stable menstruation cycles. The conclusion of the article is that clinical data from randomized studies demonstrating the efficacy of the described treatments are currently not available.
  • Steiner, R., Schweiz. Rundsch. Med. Prax. (2000) 91 (46), pp. 1967-1974, also points out that dysfunctional uterine bleeding should be treated with, among other methods, high-dosage gestagens, estrogens or a combination of both.
  • Steiner sees a treatment regimen in the oral administration of 0.01 mg of ethinyl estradiol with 2 mg of norethisterone acetate for 8 days in decreasing dosages, namely 6, 5, 4, 3, 3, 3, 3, 3/day. Besides the hormonal approach, Steiner postulates the possibility of treating an acute bleeding situation with tranexaminic acid, up to 4×2 tablets per day.
  • Davis, A., Obstet. Gynecol. (2000) 96 (6), pp. 913-920, describes the treatment of dysfunctional uterine bleedings by a three-step administration of ethinyl estradiol (EE)/norgestimate (NGM) followed by hormone-free administration of placebo for three 28-day cycles. According to the treatment regimen, the EE dosage remains constant over 21 days (0.035 mg of EE), the NGM dose increases over 21 days (7 daily dosage units of 0.180 mg of NMG and 7 daily dosage units of 0.215 mg of NMG and 7 daily dosage units of 0.250 mg of NMG), followed by a 7-day hormone-free placebo administration. The placebo-controlled study carried out by Davis included 45% of women with increased menstrual bleeding (metrorrhagia, menometrorrhagia and polymenorrhea) and about 55% of women with reduced menstrual bleeding (oligomenorrhea). The highest degree of success compared to placebo was achieved in women with reduced menstrual bleeding in whom regular withdrawal bleeding was induced. Oligomenorrhea is not necessarily a component of the DUB symptom group and is not recognized as an ailment worthy of treatment.
  • U.S. Pat. No. 6,782,282 discloses that generally extended use (3 months) of oral contraceptives can be used for the treatment of menorrhagia—a form of dysfunctional uterine bleeding.
    • SUMMARY OF THE INVENTION
  • The object of the present invention is to provide a multiphase combination preparation and a method for using it to treat dysfunctional uterine bleeding so that the extent of the bleeding is generally reduced and the recurrence of dysfunctional bleeding is generally prevented, while at the same time ensuring reliable, safe and well-tolerated oral contraception.
  • By the term “dysfunctional uterine bleeding” here means extended menstrual bleeding lasting more than 7 days with an interval between bleeding episodes of less than or equal to 21 days, or increased bleeding of more than or equal to 80 ml without an organic cause.
  • According to the invention this objective is attained by a multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception, which is based on a combination of either estradiol valerate or estradiol with 17α-cyano-methyl-17β-hydroxyestra-4, 9-dien-3-one (dienogest). The multiphase combination preparation contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate or of less than 3 mg estradiol; a second phase of 2 groups of daily dosage units, including a first group consisting of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol, and a second group consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol; a third phase consisting of 2 daily dosage units, each consisting of 1 mg of estradiol valerate or less than 1 mg of estradiol and another phase of 2 daily dosage units of a pharmaceutically harmless placebo. The total number of daily dosage units of the multiphase combination preparation and the pharmaceutically harmless placebo should be sufficient for 28 days.
  • The duration of use comprises at least one treatment cycle and depends on the individual desires of the woman regarding contraception.
  • In a preferred embodiment of the multiphase combination preparation each daily dosage unit of the first phase consists of 2.25 mg of estradiol; each daily dosage unit of the second phase contains only 1.5 mg of estradiol; and each daily dosage units of the third phase consists of 0.75 mg of estradiol.
  • In another preferred embodiment of the multiphase combination preparation each daily dosage unit of the first phase consists of 3 mg of estradiol valerate; each daily dosage unit of the second phase contains 2 mg of estradiol valerate; and each daily dosage unit of the third phase consists of 1 mg of estradiol valerate.
    • Studies of the Efficacy of the Claimed Formulation
  • 180 women 18 to 50 years of age with DUB symptoms, in whom an organic cause of the symptoms had been excluded by appropriate diagnostic methods (transvaginal ultrasound, hormone determination in the blood) and who had given their written consent to participate in the study, were treated in a randomized, double-blind, placebo-controlled clinical study. 120 women received estradiol valerate and dienogest in accordance with the claimed combination and 60 women received placebo.
  • The study comprised a run-in phase of 90 days during which the severity of the bleeding disturbances was recorded, 6 treatment cycles and one post-treatment cycle (follow-up phase).
  • The extent of bleeding was determined quantitatively by the alkaline hematin method. To this end, the women collected the monthly discharges during the entire study period and gave them to the testing center. The duration of the bleeding and the duration of the bleeding-free intervals were recorded by daily documentation in an electronic journal.
  • While the invention has been illustrated and described as embodied in a combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same, it is not intended to be limited to the details shown, since various modifications and changes may be made without departing in any way from the spirit of the present invention.
  • Without further analysis, the foregoing will so fully reveal the gist of the present invention that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this invention.
  • What is claimed is new and is set forth in the following appended claims.

Claims (7)

1. A multiphase combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding, said combination preparation containing a first phase consisting of two daily dosage units, each consisting of 3 mg of estradiol valerate or of less than 3 mg of estradiol;
a second phase consisting of two groups of daily dosage units, a first group of which consisting of 5 daily dosage units, each consisting of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol, and a second group of which consisting of 17 daily dosage units, each consisting of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or with less than 2 mg of estradiol;
a third phase consisting of two daily dosage units, each consisting of 1 mg of estradiol valerate or of less than 1 mg of estradiol;
and another phase consisting of two daily dosage units of a pharmaceutically harmless placebo;
so that the multiphase combination preparation consists of a total number of 28 daily dosage units.
2. The multiphase combination preparation as defined in claim 1, wherein each of said daily dosage units of said first phase consists of 2.25 mg of said estradiol; each of said daily dosage units of said second phase consists of 1.5 mg of said estradiol; and each of said daily dosage units of said third phase consists of 0.75 mg of said estradiol.
3. The multiphase combination preparation as defined in claim 1, wherein each of said daily dosage units of said first phase consists of 3 mg of said estradiol valerate; each of said daily dosage units of said second phase consists of 2 mg of said estradiol valerate; and each of said daily dosage units of said third phase consists of 1 mg of said estradiol valerate.
4. A method of treating dysfunctional uterine bleeding and of oral contraception, said method comprising the steps of:
a) providing a multiphase combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding, said combination preparation containing a first phase consisting of two daily dosage units, each consisting of 3 mg of estradiol valerate or of less than 3 mg of estradiol; a second phase consisting of two groups of daily dosage units, a first group of which consisting of 5 daily dosage units, each of which consist of a combination of 2 mg of dienogest with 2 mg of estradiol valerate or less than 2 mg of estradiol, and a second group of which consisting of 17 daily dosage units, each of which consist of a combination of 3 mg of dienogest with 2 mg of estradiol valerate or less than 2 mg of estradiol; a third phase consisting of 2 daily dosage units, each consisting of 1 mg of estradiol valerate or less than 1 mg of estradiol; and another phase of 2 daily dosage units of a pharmaceutically harmless placebo; so that the multiphase combination preparation consists of a total number of 28 daily dosage units; and
b) administering said multiphase combination preparation to a woman in need of treatment for dysfunctional uterine bleeding over at least one treatment cycle.
5. The method as defined in claim 4, wherein said at least one treatment cycle consists of six treatment cycles.
6. The method as defined in claim 4, wherein each of said daily dosage units of said first phase consists of 2.25 mg of said estradiol; each of said daily dosage units of said second phase consists of 1.5 mg of said estradiol; and each of said daily dosage units of said third phase consists of 0.75 mg of said estradiol.
7. The method as defined in claim 4, wherein each of said daily dosage units of said first phase consists of 3 mg of said estradiol valerate; each of said daily dosage units of said second phase consists of 2 mg of said estradiol valerate; and each of said daily dosage units of said third phase consists of 1 mg of said estradiol valerate.
US12/726,804 2005-10-17 2010-03-18 Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same Abandoned US20100190757A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/726,804 US20100190757A1 (en) 2005-10-17 2010-03-18 Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72759205P 2005-10-17 2005-10-17
US11/377,693 US20070088011A1 (en) 2005-10-17 2006-03-16 Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US11/609,705 US8153616B2 (en) 2005-10-17 2006-12-12 Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US12/726,804 US20100190757A1 (en) 2005-10-17 2010-03-18 Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/609,705 Continuation US8153616B2 (en) 2005-10-17 2006-12-12 Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

Publications (1)

Publication Number Publication Date
US20100190757A1 true US20100190757A1 (en) 2010-07-29

Family

ID=46326804

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/609,705 Active 2028-01-30 US8153616B2 (en) 2005-10-17 2006-12-12 Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US12/726,804 Abandoned US20100190757A1 (en) 2005-10-17 2010-03-18 Combination preparation for oral contreaception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/609,705 Active 2028-01-30 US8153616B2 (en) 2005-10-17 2006-12-12 Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same

Country Status (1)

Country Link
US (2) US8153616B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (en) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US20070088011A1 (en) * 2005-10-17 2007-04-19 Susan Zeun Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (en) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583129A (en) * 1993-12-22 1996-12-10 Spona; Juergen Composition for contraception

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (en) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Use of hormones for contraception
DE2431704A1 (en) 1974-07-02 1976-01-22 Asche Ag Three-stage combination oral contraceptives - contg. oestrogen with increasing doses of gestagen
US3939600A (en) * 1974-10-30 1976-02-24 Eid Ellen G Take-apart toy
DE2645307A1 (en) 1976-10-05 1978-04-06 Schering Ag NEW MEANS AND NEW METHODS FOR TREATING CLIMATE FAILURE
US4272270A (en) 1979-04-04 1981-06-09 Petrochem Consultants, Inc. Cryogenic recovery of liquid hydrocarbons from hydrogen-rich
US4290531A (en) * 1979-10-15 1981-09-22 Lazarus Iii Fred Device for holding cooking pots and lids
NL8001593A (en) 1980-03-18 1981-10-16 Akzo Nv MULTI-PHASIC COMBINATION PREPARATION FOR ORAL ANTI-CONCEPTION.
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (en) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Three-phase product for contraception composed of ethinylestradiol and lynestrenol
DE3347125A1 (en) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen MULTI-STAGE COMBINATION PREPARATION AND ITS USE FOR ORAL CONTRACTION
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
IE61236B1 (en) 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (en) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4308406C1 (en) 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4313926A1 (en) 1993-04-28 1994-11-03 Jenapharm Gmbh Multiphase pharmaceutical product for hormonal contraception
DE4339934C2 (en) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Anti-ovulation agent for hormonal contraception
NL9301562A (en) 1993-09-09 1995-04-03 Saturnus Ag Substitution therapy preparation.
DE4429374C1 (en) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component
DE19525017A1 (en) 1995-06-28 1997-01-02 Schering Ag Pharmaceutical combination preparation, kit and method for hormonal contraception
DE19540253C2 (en) 1995-10-28 1998-06-04 Jenapharm Gmbh Multi-phase preparation for contraception based on natural estrogens
US20050032756A1 (en) 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
US5858405A (en) 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
PT917466E (en) 1996-07-26 2004-12-31 Wyeth Corp ORAL CONTRACEPTIVE
ES2223081T3 (en) 1996-07-26 2005-02-16 Wyeth MONOFASTIC ORAL ANTICONCEPTIVE METHOD AND KIT THAT INCLUDES A COMBINATION OF PROGESTINE AND STROGEN.
AU3888597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US6987101B1 (en) 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
DE19654609A1 (en) 1996-12-20 1998-06-25 Schering Ag Therapeutic progestogens for the treatment of premenstrual dysphoric disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19908762A1 (en) 1999-02-18 2000-08-31 Jenapharm Gmbh Use of dienogest in high doses
DE10045380A1 (en) 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
US6699820B2 (en) 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
EP1434586A1 (en) 2001-09-29 2004-07-07 Solvay Pharmaceuticals GmbH Estrogen/gestagen combination preparation and application thereof
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
DE602004018921D1 (en) 2003-06-25 2009-02-26 Bayer Schering Pharma Ag D DIENOGEST
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
MX2007004120A (en) 2004-10-07 2007-06-15 Duramed Pharmaceuticals Inc Methods of hormonal treatment utilizing ascending-dose extended cycle regimens.
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
DK1787649T3 (en) 2005-10-13 2009-06-02 Bayer Schering Pharma Ag Use of estradiovalerate in combination with dienogest for oral treatment of dysfunctional uterine haemorrhage in unit with oral contraception
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583129A (en) * 1993-12-22 1996-12-10 Spona; Juergen Composition for contraception

Also Published As

Publication number Publication date
US20070111977A1 (en) 2007-05-17
US8153616B2 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
Reinsch et al. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study
Golobof et al. The current status of oral contraceptives: progress and recent innovations
CZ302568B6 (en) Triphasic oral contraceptive composition
Benagiano et al. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives
World Health Organization Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone
Harada et al. Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial
Endrikat et al. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone
Machado et al. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study
US8153616B2 (en) Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
Szarewski et al. 50 years of “The Pill”: celebrating a golden anniversary
KR101218872B1 (en) Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
Lal et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system
US20070088011A1 (en) Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US20070088010A1 (en) Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
Cameron Contraception and gynaecological care
ES2382459T3 (en) Use of estradiol valerate, in combination with dienogest for oral therapy of dysfunctional uterine bleeding, in conjunction with oral contraception
Ziaei et al. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route
Reape Current contraceptive research and development
Dunson et al. A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives
Yuzpe Postcoital contraception
Ashok et al. Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception
CA2624380A1 (en) Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding
Castracane et al. Changes in oral contraceptive design since the original release. Commentary on The biological history of the Pill by Roy O. Greep
Gadomska et al. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim®) in the treatment of menopausal symptoms
Van Leusden et al. Bleeding pattern, endometrial histology and efficacy of transdermal estradiol and sequential estradiol/norethisterone acetate

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载